首页 > 市场调查报告书 > 製药

非专利药

市场调查报告书

商品编码

1561032

学名药市场规模、份额、成长分析、按类型、按品牌、按适应症、按给药途径、按分销管道、按地区 - 行业预测，2024-2031 年

Generic Drugs Market Size, Share, Growth Analysis, By Type, By Brand, By Indication, By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2024-2031

出版日期: 2024年09月18日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球学名药市场规模为4074亿美元，从2023年的4235亿美元增长到2031年的5707亿美元，预计在预测期内（2024-2031年）复合年增长率为3.8%。

近年来，全球学名药市场经历了显着增长，受到几个关键因素的推动，包括品牌药专利到期、医疗保健成本上升以及对负担得起的治疗方案的需求。许多重磅药物专利保护的结束提高了学名药的可用性，这导致非专利药製造商进入市场并加剧竞争。这种竞争正在压低药品价格并改善患者获得基本药物的机会。心血管疾病、糖尿病和癌症等慢性疾病的增加进一步增加了对具有成本效益的治疗方法的需求，并增加了学名药的吸引力。此外，各国政府和医疗保健系统都推出了支持学名药使用的政策，旨在降低医疗保健成本并改善药品的获取，特别是在新兴市场。简化核准流程和完善法律规范的努力也有助于市场扩张。儘管成长，学名药市场仍面临一些挑战。学名药的核准流程复杂，各国监管情况不同，需要提供与原厂药的生物等效性证明，并且需要大量的研发投资。学名药和品牌药公司之间的智慧财产权问题和法律纠纷也可能对市场进入构成障碍。此外，儘管进行了严格的测试并遵守安全标准，学名药的品质和有效性仍令人担忧。在患者和医疗保健提供者之间建立信任对于更广泛的接受至关重要。此外，这是一个竞争激烈的市场，许多公司都在争夺市场占有率，这给利润率带来了压力，并需要在研究、开发和分销方面持续投资才能保持竞争力。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Teva Pharmaceuticals Industries Ltd.,（Israel）
Novartis AG,（Switzerland）
Pfizer Inc.,（US）
Sun Pharmaceutical Industries Ltd.,（India）
Fresenius SE & Co. KGaA.（Germany）
Lupin（India）
Endo International plc.,（Ireland）
Aurobindo Pharma（India）
Novartis AG（Switzerland）
Hikma Pharmaceuticals PLC.（UK）
STADA Arzneimittel AG（Germany）
Eli Lilly and Company（US）
Aspen Holdings（South Africa）
Dr. Reddy's Laboratories Ltd.（India）
Zydus Cadila（India）
Amgen Inc.（US）
Boehringer Ingelheim（Germany）
Baxter International Inc.（US）
MediGene AG（Germany）
Alvogen（US）
Sandoz International GmbH（Switzerland）
Bristol-Myers Squibb Company（US）
Recordati Industria Chimica e Farmaceutica SpA（Italy）

简介目录

Product Code: SQMIG35J2094

Global Generic Drugs Market size was valued at USD 407.4 Billion in 2022 and is poised to grow from USD 423.5 Billion in 2023 to USD 570.7 Billion by 2031, growing at a CAGR of 3.8% during the forecast period (2024-2031).

The global market for generic drugs has seen remarkable growth in recent years, fueled by several key factors including the expiration of patents for branded drugs, rising healthcare costs, and the demand for affordable treatment options. The availability of generic drugs has been bolstered by the end of patent protections for many blockbuster medications, which has allowed generic manufacturers to enter the market and increase competition. This competition has led to reduced drug prices and better access to essential medicines for patients. The growing prevalence of chronic conditions such as cardiovascular diseases, diabetes, and cancer has further driven the need for cost-effective treatments, enhancing the appeal of generic drugs. Additionally, various governments and healthcare systems have introduced policies to support the use of generics, aiming to lower healthcare costs and improve medication accessibility, particularly in emerging markets. The efforts to streamline the approval process and refine regulatory frameworks have also contributed to market expansion. Despite its growth, the generic drugs market faces several challenges. A complex and varying regulatory landscape across countries can complicate the approval process for generics, which requires proving bioequivalence to brand-name drugs-a task that demands significant investment in research and development. Intellectual property issues and legal disputes between generic and brand-name companies can also create barriers to market entry. Additionally, there are concerns about the perceived quality and efficacy of generic drugs, despite rigorous testing and compliance with safety standards. Building trust among patients and healthcare providers is essential for wider acceptance. Furthermore, the competitive nature of the market, with numerous players striving for market share, puts pressure on profit margins and necessitates ongoing investment in research, development, and distribution to stay competitive.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Generic Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Generic Drugs Market Segmental Analysis

Global Generic Drugs Market is segmented Type, Brand, Indication, Route of Administration, End-Users, Distribution Channel, and region. Based on Type, the market is segmented into Simple Generics, and Super Generics. Based on Brand, the market is segmented into Pure Generic, and Branded Generic. Based on Indication, the market is segmented into Central Nervous System (CNS), Cardiovascular, Dermatology, Oncology, and Respiratory Others. Based on Route of Administration, the market is segmented into Oral, Topical, Parenteral, and Others. Based on End-Users, the market is segmented into Hospitals, Homecare, Specialty Clinics, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Generic Drugs Market

The increasing global prevalence of chronic diseases, including cardiovascular disorders, diabetes, respiratory conditions, and cancer, is fueling the demand for generic drugs. These cost-effective alternatives offer an affordable way to manage and treat these persistent health issues. As more individuals seek budget-friendly options for long-term treatment, the role of generic drugs in addressing these conditions becomes more prominent. The growing incidence of these chronic illnesses highlights the need for accessible and economical treatment solutions. Generic drugs are well-positioned to meet this demand, providing effective therapies at a lower cost compared to their branded counterparts. This shift towards affordable treatment options is a significant driver behind the rising popularity and market growth of generic drugs.

Restraints in the Global Generic Drugs Market

The generic drugs market is characterized by a complex and rigorous regulatory environment. Manufacturers must navigate detailed approval procedures, including proving bioequivalence to brand-name medications. These stringent requirements can delay the introduction of generic drugs to the market and lead to higher costs for producers. The challenges associated with regulatory compliance can significantly impact the speed and expense of bringing generic drugs to market. The need to meet comprehensive standards and demonstrate that generic drugs perform identically to their branded counterparts can create hurdles for manufacturers, affecting their ability to efficiently compete and innovate.

Market Trends of the Global Generic Drugs Market

The market has seen a growing trend of consolidation, where larger pharmaceutical companies are acquiring smaller generic drug manufacturers or entering into strategic partnerships. This consolidation strategy is designed to broaden product offerings, boost manufacturing capabilities, and extend market reach. By merging with or acquiring smaller firms, major pharmaceutical companies aim to strengthen their market position and streamline operations. These moves help them to integrate new technologies, enhance production efficiency, and access a wider range of generic drug products, ultimately improving their competitive edge in the market.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Ecosystem of the Market
Trade Analysis
Supply chain Analysis
Case study Analysis
Patent Analysis
Customer & Buying Criteria Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Generic Drugs Market by Type

Market Overview
Simple Generics
Super Generics

Generic Drugs Market by Brand

Market Overview
Pure Generic
Branded Generic

Generic Drugs Market by Indication

Market Overview
Central Nervous System (CNS)
Cardiovascular
Dermatology
Oncology
Respiratory
Others

Generic Drugs Market by Route of Administration

Market Overview
Oral
Topical
Parenteral
Others

Generic Drugs Market by End-Users

Market Overview
Hospitals
Homecare
Specialty Clinics
Others

Generic Drugs Market by Distribution Channel

Market Overview
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

Generic Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Teva Pharmaceuticals Industries Ltd., (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG, (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc., (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd., (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius SE & Co. KGaA. (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Endo International plc., (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals PLC. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
STADA Arzneimittel AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aspen Holdings (South Africa)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zydus Cadila (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MediGene AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alvogen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz International GmbH (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Recordati Industria Chimica e Farmaceutica S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments